Heart Disease Trial, Recruiting (NCT05174351)

Heart Disease Trial, Recruiting NCT05174351 Sponsor: UConn Health Condition: Heart Disease

Printed from Voxsanity (voxsanity.com.au) — NCT05174351 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Heart Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People aged between 50 and 80 years old
People who have been diagnosed with a stable form of heart failure where the heart's pumping function is preserved (known as HFpEF), with symptoms classified as moderate (NYHA Class II–III) or a specific elevated blood marker related to heart stress (BNP of 100 or above)
People whose heart ultrasound (echocardiogram) shows a pumping function of 50% or more, along with a moderate or severe problem with the heart's ability to relax between beats (Grade 2 or 3 diastolic dysfunction)
People who are currently taking a water tablet (loop diuretic) on an ongoing basis
People who are currently taking a type of heart medication called a beta-blocker

Who may not be able to join:

People whose beta-blocker was prescribed specifically to treat another heart condition, such as an irregular heartbeat (atrial fibrillation) or blocked heart arteries (coronary artery disease)
People whose resting heart rate is above 100 beats per minute
People who have been hospitalised due to heart failure within the past 3 months
People who do not speak English

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Kai Chen, MD,PhD, UConn Health

Phone: 860-679-3343

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05174351

Sponsor: UConn Health

Phase: Not Applicable

Status: Recruiting

Condition: Heart Disease

Trial contact: 860-679-3343

More information: https://clinicaltrials.gov/study/NCT05174351

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People aged between 50 and 80 years old
People who have been diagnosed with a stable form of heart failure where the heart's pumping function is preserved (known as HFpEF), with symptoms classified as moderate (NYHA Class II–III) or a specific elevated blood marker related to heart stress (BNP of 100 or above)
People whose heart ultrasound (echocardiogram) shows a pumping function of 50% or more, along with a moderate or severe problem with the heart's ability to relax between beats (Grade 2 or 3 diastolic dysfunction)
People who are currently taking a water tablet (loop diuretic) on an ongoing basis
People who are currently taking a type of heart medication called a beta-blocker

Who may not be able to join:

People whose beta-blocker was prescribed specifically to treat another heart condition, such as an irregular heartbeat (atrial fibrillation) or blocked heart arteries (coronary artery disease)
People whose resting heart rate is above 100 beats per minute
People who have been hospitalised due to heart failure within the past 3 months
People who do not speak English

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

UConn Health

Registry

ClinicalTrials.gov

Start date

20 December 2021

Est. completion

1 November 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Changes in KCCQ-23 score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov